Viatris (VTRS) Stock News

Viatris (NASDAQ:VTRS) announced positive top-line results from its VEGA-3 Phase 3 trial for MR-141, a treatment for presbyopia. The randomized, placebo-controlled study involving 545 patients met its primary and all secondary endpoints, demonstrating significant improvement in near vision without compromising distance vision.

The trial showed statistically significant results (p<0.0001) in achieving ≥3-line gain in binocular distance-corrected near visual acuity. Patients reported significant functional benefits and satisfaction with near vision improvements, particularly in dim lighting conditions. The safety profile remained consistent with previous trials, with no treatment-related serious adverse events.

Viatris plans to submit an FDA application in H2 2025 for MR-141, targeting a condition that affects approximately 90% of U.S. adults over 45.

Viatris (NASDAQ: VTRS) has announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a webcast at 8:30 a.m. ET on the same day where executives will discuss the quarterly performance. Investors and the public can access the live webcast through investor.viatris.com or by calling 844.308.3344 (US) or 412.317.1896 (international). A replay of the webcast will be made available on the company's website for later viewing.

Viatris (NASDAQ: VTRS) announced positive Phase 3 LYNX-2 trial results for MR-142, a potential first-in-class treatment for night driving impairment in keratorefractive patients. The trial, involving 199 patients under FDA Special Protocol Assessment, met its primary endpoint with significantly more patients achieving ≥15-letter gain in mesopic low contrast visual acuity compared to placebo. MR-142 demonstrated patient-reported benefits in reducing difficulties with oncoming headlights and glare while driving. The drug showed no tachyphylaxis over 6 weeks and maintained a consistent safety profile. The FDA granted Fast Track designation for MR-142, potentially accelerating its development for treating chronic night driving impairment. A second pivotal study, LYNX-3, is expected to begin soon with results anticipated in H1 2026.

Viatris (VTRS) reported Q1 2025 financial results with total revenues of $3.3 billion, down 11% year-over-year, but in line with expectations. The company posted a net loss of $3.0 billion, primarily due to a $2.9 billion goodwill impairment charge. Key metrics include adjusted EBITDA of $923 million and adjusted EPS of $0.50. Viatris returned over $450 million to shareholders year-to-date through share repurchases and dividends. The company made significant pipeline progress with three positive Phase 3 data readouts, including EFFEXOR for Japan, a novel meloxicam formulation, and XULANE LO contraceptive patch. Viatris reaffirmed its 2025 guidance with total revenues expected between $13.5-14.0 billion and adjusted EPS of $2.16-2.30.

Viatris (NASDAQ: VTRS) announced positive Phase 3 study results for its investigational XULANE LO™ low dose contraceptive patch. The study, involving 1,272 women across 81 sites in the U.S., Puerto Rico, and Canada, demonstrated favorable efficacy with a Pearl Index of 4.14 and a 3.7% cumulative pregnancy probability over 13 cycles.

The patch showed strong performance metrics, including excellent adhesion with only 1.3% of patches completely detaching during the seven-day wearing period and less than 1% of subjects reporting severe local application site reactions. Most treatment emergent adverse events were mild-to-moderate, with favorable cycle control and low unscheduled bleeding events. Viatris plans to submit a New Drug Application to the FDA in the second half of 2025.

Viatris (NASDAQ: VTRS) announced positive Phase 3 results for its novel fast-acting meloxicam (MR-107A-02) for treating moderate-to-severe acute pain. Two pivotal studies following herniorrhaphy and bunionectomy surgeries demonstrated statistically significant and clinically meaningful improvements in pain control compared to placebo and opioid treatment. Key findings include: - Significant pain improvement vs placebo in both surgeries (p0.001) - Higher rates of opioid-free patients: 72.6% vs 58.6% in herniorrhaphy, 56.9% vs 33.1% in bunionectomy - Superior pain control compared to tramadol - Generally well-tolerated safety profile Viatris plans to submit a , positioning MR-107A-02 as a potential first-line, non-opioid treatment option for acute pain management.

Viatris (NASDAQ: VTRS) has announced a quarterly dividend payment of $0.12 per share for its common stock shareholders. The dividend was declared by the company's Board of Directors on May 5, 2025. Shareholders who own VTRS stock as of the close of business on May 23, 2025 (record date) will receive the dividend payment on June 16, 2025.

Viatris (NASDAQ: VTRS) has announced significant changes to its Board of Directors. Frank D'Amelio, former Pfizer CFO, and Dr. Michael Severino, current CEO of Tessera Therapeutics, have been appointed as new board members. Meanwhile, current directors Rajiv Malik and Harry Korman will retire at the end of their terms in December 2025.

D'Amelio brings 20 years of experience as a public company CFO, including 15 years at Pfizer where he managed corporate finance functions and global supply. Severino's background includes serving as Vice Chairman and President of AbbVie, where he also held roles as EVP of R&D and Chief Scientific Officer. He previously spent 10 years at Amgen in various leadership positions.

The appointments are part of Viatris' ongoing Board refreshment efforts aimed at accelerating shareholder return and positioning the company for long-term growth.

Viatris (Nasdaq: VTRS), a global healthcare company, has announced its participation in the BofA Securities 2025 Healthcare Conference in Las Vegas. The presentation is scheduled for Tuesday, May 13, 2025, at 5 p.m. PT / 8 p.m. ET.

Investors and interested parties can access a live webcast of the presentation through investor.viatris.com. An archived version will also be available for -time viewing at the same location following the live event.